Literature DB >> 10458396

Topical steroid treatment of phimosis in boys.

C C Chu1, K C Chen, G Y Diau.   

Abstract

PURPOSE: We evaluate whether steroid application alone or retraction and hygiene are responsible for successful results in boys treated with topical steroids for phimosis.
MATERIALS AND METHODS: A prospective study was performed, which included a control group of 42 patients with phimosis seen at our outpatient department from January to June 1997. During that time we trained the parent to retract and clean the foreskin only. From July 1997 to June 1998 topical steroid cream was prescribed in addition to retraction and hygiene in 276 boys with phimosis. All cases were divided into 3 subgroups of asymptomatic, symptomatic and buried penis.
RESULTS: The response rate was greater than 95% in patients who received topical steroid treatment in addition to improved hygiene. Only 13 boys (less than 5%) had no response to steroid treatment. Of the control patients 23 (55%) had no response to gentle retraction and personal hygiene. There was a significant difference (p<0.001) in response rate between the study and control groups. However, the subgroup with a buried penis responded poorly to steroid, retraction and hygiene treatment. There was significant difference (p<0.001) in response rate between the buried penis and other steroid groups but no significant difference (p>0.05) in the control group.
CONCLUSIONS: Phimosis is a physiological condition in neonates due to natural adhesion between the foreskin and the glans. Chronic infection due to poor hygiene is responsible for most cases of childhood phimosis. Circumcision is the traditional treatment of choice for phimosis or unretractable foreskin, although it is not always desired by parents or surgeons. Topical steroid cream is an easy, safe and nonsurgical alternative for phimosis. However, boys with a buried penis are not good candidates for steroid treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458396     DOI: 10.1097/00005392-199909010-00078

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Topical hydrocortisone and physiotherapy for nonretractile physiologic phimosis in infants.

Authors:  Jung Won Lee; Su Jin Cho; Eun Ae Park; Seung Joo Lee
Journal:  Pediatr Nephrol       Date:  2006-06-22       Impact factor: 3.714

Review 2.  Is steroids therapy effective in treating phimosis? A meta-analysis.

Authors:  Jiaming Liu; Jin Yang; Yuntian Chen; Sihang Cheng; Chao Xia; Tuo Deng
Journal:  Int Urol Nephrol       Date:  2016-01-02       Impact factor: 2.370

3.  Phimosis and topical steroids: new clinical findings.

Authors:  Nicola Zampieri; Michele Corroppolo; Veronica Zuin; Sanzio Bianchi; Francesco Saverio Camoglio
Journal:  Pediatr Surg Int       Date:  2007-02-17       Impact factor: 1.827

4.  Topical steroid application versus circumcision in pediatric patients with phimosis: a prospective randomized placebo controlled clinical trial.

Authors:  Ciro Esposito; Antonella Centonze; Francesca Alicchio; Antonio Savanelli; Alessandro Settimi
Journal:  World J Urol       Date:  2007-12-19       Impact factor: 4.226

5.  Long standing balanitis xerotica obliterans resulting in renal impairment in a child.

Authors:  Gideon Sandler; Emily Patrick; Danny Cass
Journal:  Pediatr Surg Int       Date:  2008-06-28       Impact factor: 1.827

Review 6.  Preputioplasty as a surgical alternative in treatment of phimosis.

Authors:  Daniar Osmonov; Claudius Hamann; Ahmed Eraky; Almut Kalz; Diethild Melchior; Robert Bergholz; Javier Romero-Otero
Journal:  Int J Impot Res       Date:  2021-12-01       Impact factor: 2.408

7.  Phimosis in children.

Authors:  Sukhbir Kaur Shahid
Journal:  ISRN Urol       Date:  2012-03-05

8.  Efficacy of topical steroid treatment in children with severe phimosis in China: A long-term single centre prospective study.

Authors:  Guanglun Zhou; Man Jiang; Zhilin Yang; Wanhua Xu; Shoulin Li
Journal:  J Paediatr Child Health       Date:  2021-07-02       Impact factor: 1.929

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.